global+growth

Eleven U.S. state-treasurers are asking drugmaker Gilead Sciences to lower the price of its experimental remdesivir treatment for Covid-19, arguing the company is attempting to market an “old drug at prices that are disconnected from economic reality.”

Some 156 nations have joined a global scheme for fair distribution of future vaccines against COVID-19, an alliance led by the World Health Organization (WHO).

As government and private money pour into the global race for a Covid-19 vaccine, drugmakers are under great pressure to keep the shot affordable while also keeping investors happy.

How a Monopoly on Remdesivir Led to Rationing

Japan said on Tuesday it has committed 17.2 billion yen ($165 million) in funds for its participation in the World Health Organization’s COVID-19 vaccine programme.

As China publicly claims it is closing in on a coronavirus vaccine, Beijing has begun promising early access to countries of strategic interest.

With pledges of a coronavirus vaccine, China is on a charm offensive to repair strained diplomatic ties and bolster engagement with other countries.

Evolution of the COVID-19 vaccine development landscape.

India is known as "the pharmacy of the world," and the nickname is well-deserved.

Germany might be on its way to filling the void left by the U.S. in global health. But it’s not going to admit it.

The United States, Japan, Britain and the European Union have struck their own deals to secure millions of COVID-19 vaccine doses for their citizens, ignoring the U.N. body’s warnings that “vaccine nationalism” will squeeze supplies.

The drug costs up to Rs 7,000 in India and around 20,000 Nepal.

The WHO has an Aug. 31 deadline for wealthier nations to join the “COVAX Global Vaccines Facility” for sharing vaccine hopefuls with developing countries.

The genesis of the East African Community’s Medicines Regulatory Harmonization initiative.

Intellectual-property disputes throughout the drug supply chain could hold back a Covid-19 shot.